BR9815171A - Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios. - Google Patents
Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios.Info
- Publication number
- BR9815171A BR9815171A BR9815171-1A BR9815171A BR9815171A BR 9815171 A BR9815171 A BR 9815171A BR 9815171 A BR9815171 A BR 9815171A BR 9815171 A BR9815171 A BR 9815171A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- optionally substituted
- cycloalkylalkyl
- cycloalkenyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Patente de Invenção de "de <B>"COMPOSTO INIBIDOR DE PDE IV APLICáVEL NO TRATAMENTO DE DOENçAS, PARTICULAMENTE DE ASMA, EM MAMìFEROS E MéTODO PARA TRATAR UM PACIENTE SOFRENDO ESTADOS DOENTIOS"<D>. A invenção apresenta a seguinte fórmula: onde R³ é selecionado do grupo consistindo de C~ 1-10~ alquil, C~ 1-10~ alquenil, C~ 3-10~ cicloalquil, C~ 4-10~ cicloalquilalquil ou C~ 3-10~ cicloalquenil, onde o referido alquil, alquenil, cicloalquil, cicloalquilalquil ou cicloalquenil é opcionalmente substituído em uma posição por hidroxi; ou benzil, onde o referido benzil é opcionalmente substituído em uma ou duas posições por halogênio, alcoxi, cicloalcoxi, ou policicloalquil e onde a referida metade do alquil do referido alcoxi ou cicloalcoxi é opcionalmente substituída em uma posição por hidroxi; O R^ 8^ é selecionado do grupo consistindo de C~ 1-10~ alquil, C~ 1-10~ alquenil, C~ 3-10~ cicloalquil, C~ 4-10~ cicloalquilalquil ou C~ 3-10~ cicloalquenil, onde o referido alquil, alquenil, cicloalquil, cicloalquilalquil ou cicloalquenil é opcionalmente substituído em uma posição por hidroxi; ou benzil, onde o referido benzil é opcionalmente substituído em uma ou duas posições por halogênio, alcoxi, cicloalcoxi, ou policicloalquil e onde a referida metade do alquil do referido alcoxi ou cicloalcoxi é opcionalmente substituída em uma posição por hidroxi; O R^ 6a^ e R^ 6b^ são independentemente selecionados do grupo consistindo de hidrogênio, C~ 1-10~ alquil, C~ 3-10~ cicloalquil, C~ 4-10~ cicloalquilalquil ou C~ 3-10~ cicloalquenil, onde o referido alquil, alquenil, cicloalquil, cicloalquilalquil ou cicloalquenil é opcionalmente substituído em uma posição por hidroxi; desde que pelo menos um dos referidos substituintes do R³, R^ 8^, R^ 6a^ e R^ 6b^ seja ainda substituído pelo referido hidroxil;
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6937197P | 1997-12-12 | 1997-12-12 | |
| PCT/US1998/026293 WO1999031102A1 (en) | 1997-12-12 | 1998-12-11 | Purine derivatives having phosphodiesterase iv inhibition activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9815171A true BR9815171A (pt) | 2000-10-10 |
Family
ID=22088545
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9815170-3A BR9815170A (pt) | 1997-12-12 | 1998-12-10 | "método de obter composto aplicável no tratamento de asma em mamìferos" |
| BR9815171-1A BR9815171A (pt) | 1997-12-12 | 1998-12-11 | Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios. |
| BR9815169-0A BR9815169A (pt) | 1997-12-12 | 1998-12-11 | "método para formar um composto e composto aplicável no tratamento de asma em mamìferos, composição farmacêutica, método para efetivar a inibição seletiva de pde iv em mamìferos de estado de doença e método de tratar mamìfero sofrendo de estado de doença." |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9815170-3A BR9815170A (pt) | 1997-12-12 | 1998-12-10 | "método de obter composto aplicável no tratamento de asma em mamìferos" |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9815169-0A BR9815169A (pt) | 1997-12-12 | 1998-12-11 | "método para formar um composto e composto aplicável no tratamento de asma em mamìferos, composição farmacêutica, método para efetivar a inibição seletiva de pde iv em mamìferos de estado de doença e método de tratar mamìfero sofrendo de estado de doença." |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US6037470A (pt) |
| EP (3) | EP1044201A4 (pt) |
| JP (5) | JP2002508379A (pt) |
| KR (3) | KR100349385B1 (pt) |
| CN (3) | CN1294590A (pt) |
| AT (1) | ATE244243T1 (pt) |
| AU (5) | AU1722899A (pt) |
| BR (3) | BR9815170A (pt) |
| CA (3) | CA2313004A1 (pt) |
| DE (3) | DE19882892T1 (pt) |
| DK (1) | DK1045849T3 (pt) |
| ES (1) | ES2202924T3 (pt) |
| GB (2) | GB2346879B (pt) |
| HU (3) | HUP0301166A2 (pt) |
| NO (1) | NO20002998L (pt) |
| PL (1) | PL341108A1 (pt) |
| PT (1) | PT1045849E (pt) |
| TR (1) | TR200001706T2 (pt) |
| WO (5) | WO1999031103A1 (pt) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002541078A (ja) * | 1999-04-02 | 2002-12-03 | ユーロ−セルティーク，エス．エー． | ホスホジエステラーゼｉｖ阻害活性を有するプリン誘導体 |
| ATE279113T1 (de) * | 1999-08-12 | 2004-10-15 | Euro Celtique Sa | Hypoxanthin- und thiohypxanthin-verbindungen |
| CN100439370C (zh) * | 2001-02-08 | 2008-12-03 | 记忆药物公司 | 作为磷酸二酯酶4抑制剂的三氟甲基嘌呤 |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| WO2004014911A1 (en) * | 2002-08-08 | 2004-02-19 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| CA2494028A1 (en) * | 2002-08-08 | 2004-02-19 | Memory Pharmaceuticals Corporation | Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| US20040063938A1 (en) * | 2002-09-30 | 2004-04-01 | Pfizer Inc | Process for preparing haloalkyl pyrimidines |
| AU2004257277B2 (en) * | 2003-07-10 | 2011-03-31 | Achillion Pharmaceuticals, Inc. | Substituted arylthiourea derivatives useful as inhibitors of viral replication |
| TW200523262A (en) * | 2003-07-29 | 2005-07-16 | Smithkline Beecham Corp | Inhibitors of AKT activity |
| WO2005058898A2 (en) * | 2003-12-16 | 2005-06-30 | Ranbaxy Laboratories Limited | Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | 神経発生のｇａｂａ受容体媒介調節 |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| DE102006033572A1 (de) | 2006-07-20 | 2008-01-24 | Bayer Cropscience Ag | N'-Cyano-N-halogenalkyl-imidamid Derivate |
| MX2009002496A (es) | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| WO2009077760A1 (en) | 2007-12-17 | 2009-06-25 | Lux Innovate Limited | Compositions and methods for maintenance of fluid conducting and containment systems |
| BRPI1006896B1 (pt) * | 2009-01-30 | 2022-05-24 | Novartis Ag | Cloridrato de n-{(1s)-2-amino-1-[(3-fluorfenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h- pirazol-5-il)-2-tiofenocarboxamida cristalino, composição farmacêutica compreendendo o mesmo e uso do dito composto para tratar ou diminuir a gravidade de câncer e artrite |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2797416B1 (en) * | 2011-12-28 | 2017-08-09 | Global Blood Therapeutics, Inc. | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| AU2014237330A1 (en) | 2013-03-15 | 2015-09-17 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| JP6426694B2 (ja) | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| KR102293060B1 (ko) | 2013-03-15 | 2021-08-23 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| WO2015120133A1 (en) | 2014-02-07 | 2015-08-13 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| BR112018011272A2 (pt) | 2015-12-04 | 2018-11-21 | Global Blood Therapeutics Inc | regimes de dosagem para 2-hidróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi)benzaldeído |
| WO2017123766A1 (en) * | 2016-01-12 | 2017-07-20 | Sperovie Biosciences, Inc. | Compounds and compositions for the treatment of disease |
| AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| WO2020072377A1 (en) | 2018-10-01 | 2020-04-09 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
| RU2746012C2 (ru) * | 2019-05-13 | 2021-04-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ | Антидепрессантное средство для коррекции нежелательных побочных эффектов нейролептиков |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3215696A (en) * | 1965-11-02 | Substituted adenines -and preparation thereof | ||
| US2956998A (en) | 1960-10-18 | Adenine derivatives and process | ||
| US2844577A (en) * | 1958-07-22 | Certificate of correction | ||
| US2903455A (en) | 1959-09-08 | Jdnviiiiaisnvhi jo | ||
| US2697709A (en) | 1951-06-14 | 1954-12-21 | Burroughs Wellcome Co | Mercapto heterocycles and method of making |
| US2691654A (en) * | 1952-06-11 | 1954-10-12 | Buroughs Wellcome & Co U S A I | Amino heterocycles and method of making |
| US2966488A (en) | 1956-07-30 | 1960-12-27 | Shive William | Substituted alkylaminopurines |
| US2957875A (en) | 1957-11-18 | 1960-10-25 | Upjohn Co | Derivatives of purine |
| US3079378A (en) | 1960-02-01 | 1963-02-26 | Upjohn Co | Acylated psicofuranosyladenines |
| BE601946A (pt) * | 1960-03-31 | |||
| US3135753A (en) | 1961-05-10 | 1964-06-02 | Burroughs Wellcome Co | Alkylthiopurines and method |
| FR1548252A (pt) | 1961-10-13 | 1968-12-06 | ||
| IL24679A (en) * | 1965-11-24 | 1971-10-20 | Yissum Res Dev Co | Derivatives of 3-methyl purine and methods of preparing the same |
| US3669979A (en) | 1967-12-14 | 1972-06-13 | Gaf Corp | Novel process for the production of 2-benzothiazolyl-phenol and derivatives thereof employing phosphorus trichloride as a catalyst |
| US3952001A (en) | 1970-07-01 | 1976-04-20 | The Boots Company Limited | 1-Carbamoyl-1,2,4-triazoles |
| JPS5121529A (ja) | 1974-08-16 | 1976-02-20 | Hitachi Ltd | Pirorinsandometsukizeiseihimakuboshiho |
| USRE31429E (en) | 1977-02-14 | 1983-10-25 | Merck & Co., Inc. | Process for preparation of 9-(dihalobenzyl)adenines |
| GB2041359B (en) * | 1979-01-10 | 1982-12-15 | Ici Ltd | Purine derivatives and their use in the defoliation of cotton plants |
| US4241063A (en) | 1979-08-06 | 1980-12-23 | Bristol-Myers Company | Purine derivatives and their use as bronchodilators |
| US4361699A (en) | 1981-09-28 | 1982-11-30 | Merck & Co., Inc. | Novel process for the preparation of N6 -alkyl-arprinocid |
| US4407802A (en) | 1981-09-28 | 1983-10-04 | Merck & Co., Inc. | 6-Amidino-9-substituted benzyl purines |
| GB2120065B (en) | 1982-04-27 | 1986-01-02 | Michael Frederick Huber | Heating plants |
| US4492592A (en) | 1983-06-06 | 1985-01-08 | Shell Oil Company | Combined desiccation of substantially supercritical CO2 |
| JPS60260579A (ja) | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
| US4883801A (en) | 1984-09-07 | 1989-11-28 | The General Hospital Corporation | Xanthine derivative pest control agents |
| GB8510758D0 (en) | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
| WO1987006576A1 (en) | 1986-04-29 | 1987-11-05 | Pfizer Inc. | Calcium independent camp phosphodiesterase inhibitor antidepressant |
| GB8618931D0 (en) | 1986-08-02 | 1986-09-10 | Euro Celtique Sa | 6-thioxanthines |
| US5057517A (en) | 1987-07-20 | 1991-10-15 | Merck & Co., Inc. | Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents |
| US5091431A (en) | 1988-02-08 | 1992-02-25 | Schering Corporation | Phosphodiesterase inhibitors |
| EP0363320A3 (de) | 1988-10-06 | 1991-11-21 | Ciba-Geigy Ag | Substituierte 9H-Purine |
| US4971972A (en) | 1989-03-23 | 1990-11-20 | Schering Corporation | Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion |
| US5290782A (en) | 1989-09-01 | 1994-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
| ES2152207T3 (es) | 1989-10-20 | 2001-02-01 | Kyowa Hakko Kogyo Kk | Derivados condensados de la purina. |
| US5117830A (en) | 1990-11-08 | 1992-06-02 | Whitby Research, Inc. | Method of determining viability of tissue |
| US5177074A (en) | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| MX9300141A (es) | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
| DE69322254T2 (de) | 1992-01-13 | 1999-04-29 | Smithkline Beecham Corp., Philadelphia, Pa. 19101 | Pyridyl-substituierte imidazole |
| EP0607373B1 (en) | 1992-06-15 | 1997-03-19 | Celltech Therapeutics Limited | Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors |
| PT652868E (pt) | 1992-07-28 | 2005-01-31 | Aventis Pharma Ltd | Inibidores da fosfodiesterase do amp ciclico |
| GB9222253D0 (en) | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
| JP3100984B2 (ja) | 1992-12-02 | 2000-10-23 | ファイザー・インク． | 選択的ｐｄｅ▲下ｉ▼▲下ｖ▼阻害物質としてのカテコールジエーテル類 |
| GB9226830D0 (en) | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
| TW263495B (pt) | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| DE4309969A1 (de) | 1993-03-26 | 1994-09-29 | Bayer Ag | Substituierte heteroanellierte Imidazole |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| FI951367A7 (fi) | 1994-03-28 | 1995-09-29 | Japan Energy Corp | Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit) |
| US5869486A (en) | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
-
1998
- 1998-12-10 GB GB0013781A patent/GB2346879B/en not_active Expired - Fee Related
- 1998-12-10 AU AU17228/99A patent/AU1722899A/en not_active Abandoned
- 1998-12-10 US US09/209,658 patent/US6037470A/en not_active Expired - Lifetime
- 1998-12-10 US US09/209,922 patent/US6040447A/en not_active Expired - Lifetime
- 1998-12-10 BR BR9815170-3A patent/BR9815170A/pt not_active Application Discontinuation
- 1998-12-10 JP JP2000539028A patent/JP2002508379A/ja active Pending
- 1998-12-10 HU HU0301166A patent/HUP0301166A2/hu unknown
- 1998-12-10 AU AU17230/99A patent/AU1723099A/en not_active Abandoned
- 1998-12-10 WO PCT/US1998/026338 patent/WO1999031103A1/en not_active Ceased
- 1998-12-10 GB GB0013780A patent/GB2346878B/en not_active Expired - Fee Related
- 1998-12-10 US US09/209,664 patent/US6057445A/en not_active Expired - Fee Related
- 1998-12-10 AU AU17229/99A patent/AU1722999A/en not_active Abandoned
- 1998-12-10 JP JP2000539027A patent/JP2002508378A/ja active Pending
- 1998-12-10 DE DE19882892T patent/DE19882892T1/de not_active Withdrawn
- 1998-12-10 EP EP98962064A patent/EP1044201A4/en not_active Withdrawn
- 1998-12-10 DE DE19882893T patent/DE19882893T1/de not_active Withdrawn
- 1998-12-10 CN CN98812098A patent/CN1294590A/zh active Pending
- 1998-12-10 WO PCT/US1998/026340 patent/WO1999031105A1/en not_active Ceased
- 1998-12-10 CA CA002313004A patent/CA2313004A1/en not_active Abandoned
- 1998-12-10 WO PCT/US1998/026339 patent/WO1999031104A1/en not_active Ceased
- 1998-12-10 KR KR1020007005963A patent/KR100349385B1/ko not_active Expired - Fee Related
- 1998-12-10 JP JP2000539026A patent/JP2002508377A/ja active Pending
- 1998-12-11 BR BR9815171-1A patent/BR9815171A/pt not_active Application Discontinuation
- 1998-12-11 PL PL98341108A patent/PL341108A1/xx unknown
- 1998-12-11 TR TR2000/01706T patent/TR200001706T2/xx unknown
- 1998-12-11 DE DE69816127T patent/DE69816127T2/de not_active Expired - Fee Related
- 1998-12-11 US US09/210,557 patent/US6211367B1/en not_active Expired - Lifetime
- 1998-12-11 EP EP98963114A patent/EP1045850A4/en not_active Withdrawn
- 1998-12-11 KR KR1020007006407A patent/KR20010033049A/ko not_active Withdrawn
- 1998-12-11 JP JP2000539025A patent/JP3504234B2/ja not_active Expired - Fee Related
- 1998-12-11 US US09/210,556 patent/US6228859B1/en not_active Expired - Fee Related
- 1998-12-11 JP JP2000524287A patent/JP2001525412A/ja active Pending
- 1998-12-11 PT PT98963053T patent/PT1045849E/pt unknown
- 1998-12-11 KR KR1020007006328A patent/KR20010032979A/ko not_active Withdrawn
- 1998-12-11 CA CA002313150A patent/CA2313150A1/en not_active Abandoned
- 1998-12-11 CN CN98812064A patent/CN1281458A/zh active Pending
- 1998-12-11 WO PCT/US1998/026444 patent/WO1999029694A1/en not_active Ceased
- 1998-12-11 ES ES98963053T patent/ES2202924T3/es not_active Expired - Lifetime
- 1998-12-11 CN CN98813362A patent/CN1284077A/zh active Pending
- 1998-12-11 AT AT98963053T patent/ATE244243T1/de not_active IP Right Cessation
- 1998-12-11 EP EP98963053A patent/EP1045849B1/en not_active Expired - Lifetime
- 1998-12-11 HU HU0100305A patent/HUP0100305A2/hu unknown
- 1998-12-11 HU HU0100417A patent/HUP0100417A3/hu unknown
- 1998-12-11 BR BR9815169-0A patent/BR9815169A/pt not_active Application Discontinuation
- 1998-12-11 AU AU18208/99A patent/AU1820899A/en not_active Abandoned
- 1998-12-11 DK DK98963053T patent/DK1045849T3/da active
- 1998-12-11 AU AU18159/99A patent/AU747366B2/en not_active Ceased
- 1998-12-11 CA CA002314335A patent/CA2314335A1/en not_active Abandoned
- 1998-12-11 WO PCT/US1998/026293 patent/WO1999031102A1/en not_active Ceased
-
2000
- 2000-06-09 NO NO20002998A patent/NO20002998L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9815171A (pt) | Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios. | |
| MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| TW200420542A (en) | A compound having TGF β inhibition activity and a medicinal composition containing the same | |
| BR0109851A (pt) | Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste | |
| BR0208678A (pt) | Composto, composição farmacêutica, uso de um composto | |
| NZ334976A (en) | Benzonaphthyridine derivatives and their use for treating airway disorders and dermatoses | |
| MY148480A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| MXPA04012965A (es) | Inhibidores virales. | |
| WO2003057698A3 (en) | Spiroazacyclic compounds as monoamine receptor modulators | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| YU29601A (sh) | Novi estri izvedeni iz supstituisanih fenil-cikloheksil jedinjenja | |
| BR0014060A (pt) | Derivado de quinolil propil piperidina, processo para preparação do mesmo, e, composição farmacêutica | |
| WO2001044247A3 (en) | Agents and methods for the treatment of proliferative diseases | |
| BR0111980A (pt) | Amina substituìda, composto protegido, métodos para tratar um paciente que tenha ou para prevenir que um paciente contraia uma doença ou condição, para inibir a atividade da beta-secretase, para inibir a clivagem da proteìna precursora de amilóide (app), para inibir a produção do peptìdeo beta amilóide (a beta) em uma célula, para inibir a produção de placa beta0amilóide em um animal, e para tratar ou prevenir uma doença compreendendo depósitos de beta-amilóide no cérebro, composição método para produzir um complexo de beta-secretase, conjunto, e, uso de amina substituìda | |
| BR9806752A (pt) | Ftalazinonas. | |
| BR0211305A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças ou condições e uso de um composto | |
| ATE225351T1 (de) | Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel | |
| MXPA03011998A (es) | Pirrolopirimidinas como inhibidores de protein cinasa. | |
| WO2004043456A8 (en) | Cholesterol absorption inhibitors for the treatment of demyelination | |
| BR0011340A (pt) | Composto, processo para preparar o composto, composição, uso de um composto, e, método de tratar doenças alérgicas incluindo a asma brÈnquica, rinite, conjuntivite, dematose e urticária | |
| WO2005046672A3 (fr) | Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose | |
| BRPI0411285A (pt) | composto, processo para preparar um composto formulação farmacêutica, uso de um composto, e, método de prevenção ou tratamento de distúrbios | |
| WO2002062777A3 (en) | Amino ceramide-like compounds and therapeutic methods of use | |
| AU1185801A (en) | Novel compounds | |
| HK1053833A1 (zh) | 取代苯基法呢基转移酶抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |